Q32 Bio Inc.(QTTB) - 2025 Q4 - Annual Results

Exhibit 99.1 Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for a ...